Notably, CLL patients with high-risk disease such as unmutated immunoglobulin heavy chain variant region (IGHV) status, TP53 aberrations and/or a complex karyotype benefit from treatment with these novel agents compared to chemoimmunotherapy (CIT). Superior in terms of efficacy and tolerability, targeted therapies with inhibitors of Bruton’s tyrosine kinase (BTK), anti-apoptotic protein B‑cell lymphoma 2 (BCL2) and phosphoinositide 3’-kinase (PI3K) strongly shifted in the forefront of commonly accepted treatment algorithms. The treatment of patients with chronic lymphocytic leukemia (CLL) has found transformational change in the last decade.
0 Comments
Leave a Reply. |